| Volume: | 120,427 |
|---|---|
| Day's Low: | $41.45 |
| 52-wk Low: | $28.04 |
| Previous Close: | $41.45 |
| Dividend: | $0.00 |
| Market Cap: | NA |
| Avg Volume: | NA |
|---|---|
| Day's High: | $41.63 |
| 52-wk High: | $45.19 |
| Open Price: | $41.56 |
| Yield: | 0.00% |
| P/E (Forward): | NA |
| 7:56 AM | 3/19/2010 | EU Panel Backs Marketing Authorization For Nivestim |
| 6:27 PM | 3/18/2010 | Roche Increased Avastin Sales Efforts; Doubles US Force |
| 3:52 PM | 3/18/2010 | 2nd UPDATE: Roche Sees Big Potential In Experimental Drugs |
| 2:45 PM | 3/18/2010 | UPDATE: Roche Sees Blockbuster Potential In Experimental Drugs |
| 1:31 PM | 3/18/2010 | Roche Sees Blockbuster Potential In 10 Experimental Drugs |
| 10:10 AM | 3/18/2010 | Roche Sees Blockbuster Potential For Several Experimental Drugs |
| 2:23 AM | 3/18/2010 | Roche: Well Positioned For Sustainable Long-Term Growth |
| 3/14/2010 | Pressure Increases at Roche (WSJ.com) |
| 3/13/2010 | FDA Adds Warning to Plavix (WSJ.com) |
| 3/12/2010 | A Black-Box Warning for Plavix. Confusion May Follow (WSJ.com) |
| 3/12/2010 | Autos advance in mildly positive Europe (MarketWatch.com) |
| 3/10/2010 | FDA to Review Bone Drugs After Studies Report Hip Breaks (WSJ.com) |
| 3/8/2010 | AIG, MetLife, McDonald's in focus (MarketWatch.com) |
| 3/3/2010 | FDA Finds Problems With Insulin Pumps 'Across Manufacturers' (WSJ.com) |
| 3/2/2010 | Sequenom, CombinatoRx lead drug stocks north (MarketWatch.com) |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | NA | NA | NA |
| EPS, GAAP | NA | NA | NA |
| Consensus Estimate | NA | NA | NA |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | NA | NA | NA |
| EPS, GAAP | NA | NA | NA |
| Consensus Estimate | NA | NA | NA |
| RHHBY | Industry Average | |
| P/E (TTM) | NA | NA |
| P/E (Forward) | NA | NA |
| PEG Ratio | NA | NA |
| Price/Sales | NA | NA |
| Beta | NA | NA |